世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界の脳性麻痺治療市場 2019-2023年

Global Cerebral Palsy Treatment Market 2019-2023

IRTNTR30137

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2018年11月US$2,500
シングルユーザライセンス
120

サマリー

この調査レポートは世界の脳性麻痺治療市場を分析・予測したTechNavioの市場調査報告書です。

Description

About Cerebral palsy
Cerebral palsy is a commonly occurring neurological disorder that occurs in early childhood. The usually occurring symptoms of CP are effects on movement, lack of coordination, and unusual muscle tone caused by cerebral damage within the first five years of birth.
Technavio’s analysts forecast the Global Cerebral Palsy Treatment Market to grow at a CAGR of 5.42% during the period 2019-2023.

Covered in this report
The report covers the present scenario and the growth prospects of the cerebral palsy treatment market. To calculate the market size, the report considers the revenue generated by the sale of drugs for the treatment of cerebral palsy across the globe.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, cerebral palsy treatment market 2019-2023, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendor
- Allergan
- GlaxoSmithKline
- Johnson & Johnson
- Pfizer
Market driver
- Rising incidences of cerebral palsy
- For a full, detailed list, view our report

Market challenge
- Complex and multifactorial etiology
- For a full, detailed list, view our report

Market trend
- Increasing dependency of patients on medications for cerebral palsy
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2023 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.



目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: PIPELINE ANALYSIS
- Pipeline analysis
PART 05: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- Anticonvulsant drugs - Market size and forecast 2018-2023
- Antispastic drugs - Market size and forecast 2018-2023
- Anticholinergic drugs - Market size and forecast 2018-2023
- NSAIDs - Market size and forecast 2018-2023
- Antidepressants and others - Market size and forecast 2018-2023
- Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY TYPE
- Spastic cerebral palsy
- Dyskinetic cerebral palsy
- Hypotonic cerebral palsy
- Ataxic cerebral palsy
- Mixed cerebral palsy
PART 10: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Americas - Market size and forecast 2018-2023
- APAC - Market size and forecast 2018-2023
- EMEA - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 13: MARKET TRENDS
PART 14: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 15: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Allergan
- GlaxoSmithKline
- Johnson & Johnson
- Pfizer
PART 16: APPENDIX
- Research methodology
- List of abbreviations
PART 17: EXPLORE TECHNAVIO



Exhibit 01: Global CNS disorders drugs market
Exhibit 02: Segments of global cns disorders drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline molecules for cerebral palsy
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Anticonvulsant drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Anticonvulsant drugs - Year-over-year growth 2019-2023 (%)
Exhibit 22: Antispastic drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Antispastic drugs - Year-over-year growth 2019-2023 (%)
Exhibit 24: Anticholinergic drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Anticholinergic drugs - Year-over-year growth 2019-2023 (%)
Exhibit 26: NSAIDs - Market size and forecast 2018-2023 ($ millions)
Exhibit 27: NSAIDs - Year-over-year growth 2019-2023 (%)
Exhibit 28: Antidepressants and others - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Antidepressants and others - Year-over-year growth 2019-2023 (%)
Exhibit 30: Market opportunity by product
Exhibit 31: Customer landscape
Exhibit 32: Market share by geography 2018-2023 (%)
Exhibit 33: Geographic comparison
Exhibit 34: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Americas
Exhibit 37: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in APAC
Exhibit 40: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 41: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 42: Top 3 countries in EMEA
Exhibit 43: Key leading countries
Exhibit 44: Market opportunity
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: Allergan - Vendor overview
Exhibit 52: Allergan - Business segments
Exhibit 53: Allergan - Organizational developments
Exhibit 54: Allergan - Segment focus
Exhibit 55: Allergan - Key offerings
Exhibit 56: GlaxoSmithKline - Vendor overview
Exhibit 57: GlaxoSmithKline - Business segments
Exhibit 58: GlaxoSmithKline - Organizational developments
Exhibit 59: GlaxoSmithKline - Geographic focus
Exhibit 60: GlaxoSmithKline - Segment focus
Exhibit 61: GlaxoSmithKline - Key offerings
Exhibit 62: Johnson & Johnson - Vendor overview
Exhibit 63: Johnson & Johnson - Business segments
Exhibit 64: Johnson & Johnson - Organizational developments
Exhibit 65: Johnson & Johnson - Geographic focus
Exhibit 66: Johnson & Johnson - Segment focus
Exhibit 67: Johnson & Johnson - Key offerings
Exhibit 68: Pfizer - Vendor overview
Exhibit 69: Pfizer - Business segments
Exhibit 70: Pfizer - Organizational developments
Exhibit 71: Pfizer - Geographic focus
Exhibit 72: Pfizer - Segment focus
Exhibit 73: Pfizer - Key offerings


 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る